Latest from Roswell Park

A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.
To determine the 10-year oncologic outcomes and recurrence patterns after robot-assisted radical cystectomy, our group within the Department of Urology at Roswell Park Comprehensive Cancer Center performed a retrospective review.
Two Roswell Park Comprehensive Cancer Center physicians are expanding their leadership roles across the United States and abroad with recent appointments in their respective fields of specialty.
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.
Jens Hillengass, MD, discusses available imaging modalities in multiple myeloma.
James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.
Imaging approaches and technologies have advanced dramatically since the last such guidance was developed a decade ago, driving earlier and more effective detection and treatment.
James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer. 
Publication Bottom Border
Border Publication